New blood test aims to catch liver cancer recurrence early

NCT ID NCT07489768

Not yet recruiting Diagnosis Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new blood test that looks for specific DNA changes (methylation) to monitor if liver cancer comes back after treatment. Researchers will enroll 162 adults with liver cancer who have had surgery, transplant, ablation, or chemoembolization. The test's accuracy will be compared with standard clinical methods to see if it can reliably detect recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GNB4 and Riplet gene methylation blood test
What this could lead to: If successful, this blood test could help doctors detect liver cancer recurrence earlier and more accurately after treatment, potentially improving patient outcomes.
What could go wrong: This is an early-stage observational study with only 162 participants. The test may not prove accurate enough for routine use, and results may not apply to all liver cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC) HEPATOCELLULAR CARCINOMA RECURRENT

More trials for these conditions

Other studies related to the condition(s) this trial covers.